{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:00:58Z","timestamp":1780538458498,"version":"3.54.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Basic Research Program of Guizhou Province","award":["QianKeHe Basics-ZK [2023] General 583"],"award-info":[{"award-number":["QianKeHe Basics-ZK [2023] General 583"]}]},{"name":"Project of Development Center for Medical Science & Technology, National Health Commission of the PRC","award":["WKZX2022JG0105"],"award-info":[{"award-number":["WKZX2022JG0105"]}]},{"name":"S&T Major Project of Lishui City","award":["2017ZDYF15"],"award-info":[{"award-number":["2017ZDYF15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-024-03926-3","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T08:24:49Z","timestamp":1730363089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quantitative proteomics and multi-omics analysis identifies potential biomarkers and the underlying pathological molecular networks in Chinese patients with multiple sclerosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-You","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Xin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Yao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Mei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"issue":"2","key":"3926_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple Scler N Engl J Med. 2018;378(2):169\u201380.","journal-title":"Multiple Scler N Engl J Med"},{"issue":"6","key":"3926_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/jnr.24090","volume":"96","author":"H Yong","year":"2018","unstructured":"Yong H, Chartier G, Quandt J. Modulating inflammation and neuroprotection in multiple sclerosis. J Neurosci Res. 2018;96(6):927\u201350.","journal-title":"J Neurosci Res"},{"key":"3926_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"M Sospedra","year":"2005","unstructured":"Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683\u2013747.","journal-title":"Annu Rev Immunol"},{"issue":"14","key":"3926_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816\u201321.","journal-title":"Mult Scler"},{"issue":"6","key":"3926_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/glia.23940","volume":"69","author":"SP das Neves","year":"2021","unstructured":"das Neves SP, et al. Altered astrocytic function in experimental neuroinflammation and multiple sclerosis. Glia. 2021;69(6):1341\u201368.","journal-title":"Glia"},{"key":"3926_CR6","unstructured":"International Multiple Sclerosis Genetics. C., Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019. 365(6460)."},{"issue":"7359","key":"3926_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"IMS Genetics","year":"2011","unstructured":"Genetics IMS. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214\u20139.","journal-title":"Nature"},{"issue":"9","key":"3926_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa073493","volume":"357","author":"IMS Genetics","year":"2007","unstructured":"Genetics IMS. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851\u201362.","journal-title":"N Engl J Med"},{"issue":"10","key":"3926_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamaneurol.2015.1788","volume":"72","author":"R Ramanujam","year":"2015","unstructured":"Ramanujam R, et al. Effect of Smoking Cessation on multiple sclerosis prognosis. JAMA Neurol. 2015;72(10):1117\u201323.","journal-title":"JAMA Neurol"},{"issue":"3","key":"3926_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306\u201314.","journal-title":"JAMA Neurol"},{"issue":"1","key":"3926_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"3926_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S1474-4422(04)00933-0","volume":"3","author":"RA Marrie","year":"2004","unstructured":"Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004;3(12):709\u201318.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3926_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41593-022-01097-3","volume":"25","author":"M Kaufmann","year":"2022","unstructured":"Kaufmann M, et al. Identification of early neurodegenerative pathways in progressive multiple sclerosis. Nat Neurosci. 2022;25(7):944\u201355.","journal-title":"Nat Neurosci"},{"key":"3926_CR14","doi-asserted-by":"crossref","unstructured":"Sen MK et al. Proteomics of multiple sclerosis: inherent issues in defining the pathoetiology and identifying (early) biomarkers. Int J Mol Sci, 2021. 22(14).","DOI":"10.3390\/ijms22147377"},{"key":"3926_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2377-13-45","volume":"13","author":"R De Masi","year":"2013","unstructured":"De Masi R, et al. The clinical potential of blood-proteomics in multiple sclerosis. BMC Neurol. 2013;13:45.","journal-title":"BMC Neurol"},{"issue":"1","key":"3926_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12014-022-09361-1","volume":"19","author":"C Cappelletti","year":"2022","unstructured":"Cappelletti C, et al. Quantitative proteomics reveals protein dysregulation during T cell activation in multiple sclerosis patients compared to healthy controls. Clin Proteom. 2022;19(1):23.","journal-title":"Clin Proteom"},{"issue":"5","key":"3926_CR17","doi-asserted-by":"publisher","first-page":"e0122045","DOI":"10.1371\/journal.pone.0122045","volume":"10","author":"T Avsar","year":"2015","unstructured":"Avsar T, et al. CSF proteomics identifies Specific and Shared pathways for multiple sclerosis clinical subtypes. PLoS ONE. 2015;10(5):e0122045.","journal-title":"PLoS ONE"},{"issue":"16","key":"3926_CR18","doi-asserted-by":"publisher","first-page":"e1800335","DOI":"10.1002\/pmic.201800335","volume":"19","author":"V Singh","year":"2019","unstructured":"Singh V, Tripathi A, Dutta R. Proteomic approaches to Decipher mechanisms underlying pathogenesis in multiple sclerosis patients. Proteomics. 2019;19(16):e1800335.","journal-title":"Proteomics"},{"issue":"6","key":"3926_CR19","doi-asserted-by":"publisher","first-page":"e65184","DOI":"10.1371\/journal.pone.0065184","volume":"8","author":"A Fiorini","year":"2013","unstructured":"Fiorini A, et al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS ONE. 2013;8(6):e65184.","journal-title":"PLoS ONE"},{"issue":"1","key":"3926_CR20","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1038\/s41598-021-82388-w","volume":"11","author":"EF Mosleth","year":"2021","unstructured":"Mosleth EF, et al. Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. Sci Rep. 2021;11(1):4087.","journal-title":"Sci Rep"},{"issue":"11","key":"3926_CR21","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/prca.200700315","volume":"1","author":"S Elkabes","year":"2007","unstructured":"Elkabes S, Li H. Proteomic strategies in multiple sclerosis and its animal models. Proteom Clin Appl. 2007;1(11):1393\u2013405.","journal-title":"Proteom Clin Appl"},{"issue":"5","key":"3926_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1177\/1352458508101943","volume":"15","author":"JI Satoh","year":"2009","unstructured":"Satoh JI, Tabunoki H, Yamamura T. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult Scler. 2009;15(5):531\u201341.","journal-title":"Mult Scler"},{"key":"3926_CR23","doi-asserted-by":"publisher","first-page":"779003","DOI":"10.3389\/fneur.2021.779003","volume":"12","author":"NK Rai","year":"2021","unstructured":"Rai NK, et al. Comparative proteomic profiling identifies reciprocal expression of mitochondrial proteins between White and Gray Matter lesions from multiple sclerosis brains. Front Neurol. 2021;12:779003.","journal-title":"Front Neurol"},{"issue":"3","key":"3926_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/ene.12534","volume":"22","author":"MT Wallin","year":"2015","unstructured":"Wallin MT, et al. Serum proteomic analysis of a pre-symptomatic multiple sclerosis cohort. Eur J Neurol. 2015;22(3):591\u20139.","journal-title":"Eur J Neurol"},{"issue":"7182","key":"3926_CR25","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/nature06559","volume":"451","author":"MH Han","year":"2008","unstructured":"Han MH, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008;451(7182):1076\u201381.","journal-title":"Nature"},{"issue":"11","key":"3926_CR26","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/acn3.50893","volume":"6","author":"R Magliozzi","year":"2019","unstructured":"Magliozzi R, et al. Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. Ann Clin Transl Neurol. 2019;6(11):2150\u201363.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"3926_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/156652411795677981","volume":"11","author":"AS Lourenco","year":"2011","unstructured":"Lourenco AS, et al. Proteomics-based technologies in the discovery of biomarkers for multiple sclerosis in the cerebrospinal fluid. Curr Mol Med. 2011;11(4):326\u201349.","journal-title":"Curr Mol Med"},{"issue":"1\u20132","key":"3926_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jneuroim.2011.11.004","volume":"248","author":"V Singh","year":"2012","unstructured":"Singh V, et al. Proteomics technologies for biomarker discovery in multiple sclerosis. J Neuroimmunol. 2012;248(1\u20132):40\u20137.","journal-title":"J Neuroimmunol"},{"issue":"7","key":"3926_CR29","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbapap.2014.12.013","volume":"1854","author":"AC Kroksveen","year":"2015","unstructured":"Kroksveen AC, et al. Cerebrospinal fluid proteomics in multiple sclerosis. Biochim Biophys Acta. 2015;1854(7):746\u201356.","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"3926_CR30","doi-asserted-by":"publisher","first-page":"12952","DOI":"10.1073\/pnas.1912839117","volume":"117","author":"J Huang","year":"2020","unstructured":"Huang J, et al. Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117(23):12952\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"3926_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/prca.201200104","volume":"7","author":"LF Dagley","year":"2013","unstructured":"Dagley LF, Emili A, Purcell AW. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. Proteom Clin Appl. 2013;7(1\u20132):91\u2013108.","journal-title":"Proteom Clin Appl"},{"key":"3926_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jprot.2015.02.018","volume":"118","author":"H Tremlett","year":"2015","unstructured":"Tremlett H, et al. Serum proteomics in multiple sclerosis disease progression. J Proteom. 2015;118:2\u201311.","journal-title":"J Proteom"},{"issue":"9","key":"3926_CR33","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/acn3.771","volume":"6","author":"A Malekzadeh","year":"2019","unstructured":"Malekzadeh A, et al. Plasma proteome in multiple sclerosis disease progression. Ann Clin Transl Neurol. 2019;6(9):1582\u201394.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"3926_CR34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.autrev.2015.06.001","volume":"14","author":"B Fitzner","year":"2015","unstructured":"Fitzner B, Hecker M, Zettl UK. Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmun Rev. 2015;14(10):903\u201313.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"3926_CR35","doi-asserted-by":"publisher","first-page":"e12442","DOI":"10.1371\/journal.pone.0012442","volume":"5","author":"MP Stoop","year":"2010","unstructured":"Stoop MP, et al. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS ONE. 2010;5(8):e12442.","journal-title":"PLoS ONE"},{"key":"3926_CR36","doi-asserted-by":"publisher","first-page":"104219","DOI":"10.1016\/j.cellimm.2020.104219","volume":"358","author":"C Chase Huizar","year":"2020","unstructured":"Chase Huizar C, Raphael I, Forsthuber TG. Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis. Cell Immunol. 2020;358:104219.","journal-title":"Cell Immunol"},{"issue":"5","key":"3926_CR37","doi-asserted-by":"publisher","first-page":"e0217208","DOI":"10.1371\/journal.pone.0217208","volume":"14","author":"SK Bedri","year":"2019","unstructured":"Bedri SK, et al. Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment. PLoS ONE. 2019;14(5):e0217208.","journal-title":"PLoS ONE"},{"issue":"1","key":"3926_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12974-022-02404-2","volume":"19","author":"IL Salazar","year":"2022","unstructured":"Salazar IL, et al. Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis. J Neuroinflammation. 2022;19(1):44.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"3926_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1155\/2006\/670439","volume":"22","author":"KC O\u2019Connor","year":"2006","unstructured":"O\u2019Connor KC, et al. Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. Dis Markers. 2006;22(4):213\u201325.","journal-title":"Dis Markers"},{"issue":"4","key":"3926_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF03256329","volume":"13","author":"VK Harris","year":"2009","unstructured":"Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther. 2009;13(4):225\u201344.","journal-title":"Mol Diagn Ther"},{"issue":"13","key":"3926_CR41","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2174\/09298673113206660311","volume":"21","author":"B Amin","year":"2014","unstructured":"Amin B, et al. New poteintial serum biomarkers in multiple sclerosis identified by proteomic strategies. Curr Med Chem. 2014;21(13):1544\u201356.","journal-title":"Curr Med Chem"},{"issue":"8","key":"3926_CR42","doi-asserted-by":"publisher","first-page":"e103984","DOI":"10.1371\/journal.pone.0103984","volume":"9","author":"M Liguori","year":"2014","unstructured":"Liguori M, et al. Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS ONE. 2014;9(8):e103984.","journal-title":"PLoS ONE"},{"issue":"5","key":"3926_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/ana.22633","volume":"71","author":"M Komori","year":"2012","unstructured":"Komori M, et al. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol. 2012;71(5):614\u201323.","journal-title":"Ann Neurol"},{"issue":"11","key":"3926_CR44","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1021\/pr500609e","volume":"13","author":"S Bystrom","year":"2014","unstructured":"Bystrom S, et al. Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis. J Proteome Res. 2014;13(11):4607\u201319.","journal-title":"J Proteome Res"},{"issue":"1\u20132","key":"3926_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jneuroim.2010.11.003","volume":"233","author":"T Sakurai","year":"2011","unstructured":"Sakurai T, et al. Identification of antibodies as biological markers in serum from multiple sclerosis patients by immunoproteomic approach. J Neuroimmunol. 2011;233(1\u20132):175\u201380.","journal-title":"J Neuroimmunol"},{"issue":"12","key":"3926_CR46","doi-asserted-by":"publisher","first-page":"23269","DOI":"10.3390\/ijms151223269","volume":"15","author":"P Colomba","year":"2014","unstructured":"Colomba P, et al. Identification of biomarkers in cerebrospinal fluid and serum of multiple sclerosis patients by immunoproteomics approach. Int J Mol Sci. 2014;15(12):23269\u201382.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3926_CR47","doi-asserted-by":"publisher","first-page":"fcab084","DOI":"10.1093\/braincomms\/fcab084","volume":"3","author":"F Probert","year":"2021","unstructured":"Probert F, et al. Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. Brain Commun. 2021;3(2):fcab084.","journal-title":"Brain Commun"},{"key":"3926_CR48","doi-asserted-by":"publisher","first-page":"583811","DOI":"10.3389\/fnmol.2020.583811","volume":"13","author":"A Miedema","year":"2020","unstructured":"Miedema A, et al. High-resolution transcriptomic and proteomic profiling of heterogeneity of brain-derived Microglia in multiple sclerosis. Front Mol Neurosci. 2020;13:583811.","journal-title":"Front Mol Neurosci"},{"issue":"19","key":"3926_CR49","doi-asserted-by":"publisher","first-page":"9671","DOI":"10.1073\/pnas.1818347116","volume":"116","author":"E Kotelnikova","year":"2019","unstructured":"Kotelnikova E, et al. MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. Proc Natl Acad Sci U S A. 2019;116(19):9671\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3926_CR50","doi-asserted-by":"crossref","unstructured":"Cicalini I et al. Integrated Lipidomics and Metabolomics Analysis of Tears in multiple sclerosis: an insight into diagnostic potential of Lacrimal Fluid. Int J Mol Sci, 2019. 20(6).","DOI":"10.3390\/ijms20061265"},{"key":"3926_CR51","doi-asserted-by":"crossref","unstructured":"Qendro V et al. Integrative proteomics, genomics, and translational immunology approaches reveal mutated forms of Proteolipid Protein 1 (PLP1) and mutant-specific immune response in multiple sclerosis. Proteomics, 2017. 17(6).","DOI":"10.1002\/pmic.201600322"},{"issue":"4","key":"3926_CR52","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/prca.201500083","volume":"10","author":"P Del Boccio","year":"2016","unstructured":"Del Boccio P, et al. Integration of metabolomics and proteomics in multiple sclerosis: from biomarkers discovery to personalized medicine. Proteom Clin Appl. 2016;10(4):470\u201384.","journal-title":"Proteom Clin Appl"},{"issue":"1\u20132","key":"3926_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jneuroim.2012.01.001","volume":"248","author":"P Villoslada","year":"2012","unstructured":"Villoslada P, Baranzini S. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis. J Neuroimmunol. 2012;248(1\u20132):58\u201365.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"3926_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13\u201325.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"3926_CR55","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.arcmed.2014.11.018","volume":"45","author":"P Campos-Bedolla","year":"2014","unstructured":"Campos-Bedolla P, et al. Role of the blood-brain barrier in the nutrition of the central nervous system. Arch Med Res. 2014;45(8):610\u201338.","journal-title":"Arch Med Res"},{"issue":"5","key":"3926_CR56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/1352458510392619","volume":"17","author":"J Correale","year":"2011","unstructured":"Correale J, Fiol M. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler. 2011;17(5):521\u201331.","journal-title":"Mult Scler"},{"issue":"12","key":"3926_CR57","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/1744666X.2017.1400380","volume":"13","author":"J Lycke","year":"2017","unstructured":"Lycke J, Zetterberg H. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Expert Rev Clin Immunol. 2017;13(12):1143\u201353.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"3926_CR58","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jprot.2010.01.004","volume":"73","author":"J Ottervald","year":"2010","unstructured":"Ottervald J, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteom. 2010;73(6):1117\u201332.","journal-title":"J Proteom"},{"issue":"19","key":"3926_CR59","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1002\/pmic.201400142","volume":"15","author":"AC Kroksveen","year":"2015","unstructured":"Kroksveen AC, et al. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 2015;15(19):3361\u20139.","journal-title":"Proteomics"},{"issue":"8","key":"3926_CR60","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/pmic.200700446","volume":"8","author":"MP Stoop","year":"2008","unstructured":"Stoop MP, et al. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics. 2008;8(8):1576\u201385.","journal-title":"Proteomics"},{"key":"3926_CR61","doi-asserted-by":"crossref","unstructured":"Comabella M et al. CSF chitinase 3-Like 2 is Associated with Long-Term disability progression in patients with Progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm, 2021. 8(6).","DOI":"10.1212\/NXI.0000000000001082"},{"key":"3926_CR62","doi-asserted-by":"publisher","first-page":"892491","DOI":"10.3389\/fgene.2022.892491","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu H, et al. Label-free quantitative proteomic analysis of Cerebrospinal Fluid and serum in patients with relapse-remitting multiple sclerosis. Front Genet. 2022;13:892491.","journal-title":"Front Genet"},{"issue":"7","key":"3926_CR63","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/pmic.200300715","volume":"4","author":"D Dumont","year":"2004","unstructured":"Dumont D, et al. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics. 2004;4(7):2117\u201324.","journal-title":"Proteomics"},{"key":"3926_CR64","doi-asserted-by":"crossref","unstructured":"Kroksveen AC, Guldbrandsen A, Vedeler C, Myhr KM, Opsahl JA, Berven FS. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand Suppl. 2012;126(Suppl. 195):90\u20136.","DOI":"10.1111\/ane.12029"},{"issue":"7","key":"3926_CR65","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/1352458507076406","volume":"13","author":"V Lehmensiek","year":"2007","unstructured":"Lehmensiek V, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler. 2007;13(7):840\u20139.","journal-title":"Mult Scler"},{"key":"3926_CR66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/prca.201700005","volume":"11","author":"MP Stoop","year":"2017","unstructured":"Stoop MP, et al. Decreased neuro-axonal proteins in CSF at First Attack of suspected multiple sclerosis. Proteom Clin Appl. 2017;11:11\u20132.","journal-title":"Proteom Clin Appl"},{"issue":"3","key":"3926_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1191\/1352458504ms1023oa","volume":"10","author":"BN Hammack","year":"2004","unstructured":"Hammack BN, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler. 2004;10(3):245\u201360.","journal-title":"Mult Scler"},{"issue":"7","key":"3926_CR68","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1080\/00207454.2020.1837801","volume":"132","author":"E Jankovska","year":"2022","unstructured":"Jankovska E, et al. Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. Int J Neurosci. 2022;132(7):724\u201334.","journal-title":"Int J Neurosci"},{"issue":"9","key":"3926_CR69","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/j.1468-1331.2008.02239.x","volume":"15","author":"D Chiasserini","year":"2008","unstructured":"Chiasserini D, et al. CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur J Neurol. 2008;15(9):998\u20131001.","journal-title":"Eur J Neurol"},{"issue":"10","key":"3926_CR70","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1177\/1352458514561906","volume":"21","author":"G Hinsinger","year":"2015","unstructured":"Hinsinger G, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler. 2015;21(10):1251\u201361.","journal-title":"Mult Scler"},{"issue":"1","key":"3926_CR71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.nbd.2010.06.007","volume":"40","author":"VK Harris","year":"2010","unstructured":"Harris VK, et al. Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol Dis. 2010;40(1):331\u20139.","journal-title":"Neurobiol Dis"},{"key":"3926_CR72","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jprot.2012.09.037","volume":"78","author":"AC Kroksveen","year":"2013","unstructured":"Kroksveen AC, et al. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J Proteom. 2013;78:312\u201325.","journal-title":"J Proteom"},{"issue":"1\u20132","key":"3926_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2009.09.002","volume":"219","author":"A Awad","year":"2010","unstructured":"Awad A, et al. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol. 2010;219(1\u20132):1\u20137.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"3926_CR74","doi-asserted-by":"publisher","first-page":"e63172","DOI":"10.1371\/journal.pone.0063172","volume":"8","author":"M Khademi","year":"2013","unstructured":"Khademi M, et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS ONE. 2013;8(5):e63172.","journal-title":"PLoS ONE"},{"issue":"5","key":"3926_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrneurol.2013.41","volume":"9","author":"M Stangel","year":"2013","unstructured":"Stangel M, et al. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9(5):267\u201376.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"3926_CR76","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1021\/pr0504788","volume":"5","author":"JP Noben","year":"2006","unstructured":"Noben JP, et al. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res. 2006;5(7):1647\u201357.","journal-title":"J Proteome Res"},{"issue":"8A","key":"3926_CR77","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/j.1582-4934.2009.00850.x","volume":"13","author":"S Liu","year":"2009","unstructured":"Liu S, et al. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med. 2009;13(8A):1586\u2013603.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"3926_CR78","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/ana.20890","volume":"59","author":"E Meinl","year":"2006","unstructured":"Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol. 2006;59(6):880\u201392.","journal-title":"Ann Neurol"},{"issue":"1","key":"3926_CR79","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"3926_CR80","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol. 2005;58(6):840\u20136.","journal-title":"Ann Neurol"},{"issue":"7","key":"3926_CR81","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1021\/acs.jproteome.8b00235","volume":"17","author":"KR Ludwig","year":"2018","unstructured":"Ludwig KR, Schroll MM, Hummon AB. Comparison of In-Solution, FASP, and S-Trap based digestion methods for Bottom-Up proteomic studies. J Proteome Res. 2018;17(7):2480\u201390.","journal-title":"J Proteome Res"},{"issue":"D1","key":"3926_CR82","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol Y, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50(D1):D543\u201352.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3926_CR83","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"3926_CR84","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/pmic.201400392","volume":"15","author":"L Gatto","year":"2015","unstructured":"Gatto L, et al. Visualization of proteomics data using R and bioconductor. Proteomics. 2015;15(8):1375\u201389.","journal-title":"Proteomics"},{"issue":"3","key":"3926_CR85","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2(3):100141.","journal-title":"Innov (Camb)"},{"issue":"D1","key":"3926_CR86","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3926_CR87","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"4","key":"3926_CR88","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/bioinformatics\/btu684","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu G, et al. DOSE: an R\/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics. 2015;31(4):608\u20139.","journal-title":"Bioinformatics"},{"issue":"D1","key":"3926_CR89","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"3926_CR90","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1093\/bioinformatics\/bty890","volume":"35","author":"A Jain","year":"2019","unstructured":"Jain A, Tuteja G. TissueEnrich: tissue-specific gene enrichment analysis. Bioinformatics. 2019;35(11):1966\u20137.","journal-title":"Bioinformatics"},{"key":"3926_CR91","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, et al. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.","journal-title":"BMC Bioinformatics"},{"key":"3926_CR92","doi-asserted-by":"publisher","first-page":"792711","DOI":"10.3389\/fimmu.2021.792711","volume":"12","author":"F Yang","year":"2021","unstructured":"Yang F, et al. Altered plasma metabolic profiles in Chinese patients with multiple sclerosis. Front Immunol. 2021;12:792711.","journal-title":"Front Immunol"},{"key":"3926_CR93","doi-asserted-by":"publisher","first-page":"590783","DOI":"10.3389\/fimmu.2020.590783","volume":"11","author":"Z Ling","year":"2020","unstructured":"Ling Z, et al. Alterations of the fecal microbiota in Chinese patients with multiple sclerosis. Front Immunol. 2020;11:590783.","journal-title":"Front Immunol"},{"key":"3926_CR94","doi-asserted-by":"crossref","unstructured":"Porozhan Y et al. Defective integrator activity shapes the transcriptome of patients with multiple sclerosis. Life Sci Alliance, 2024. 7(10).","DOI":"10.26508\/lsa.202402586"},{"issue":"12","key":"3926_CR95","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1007\/s12031-021-01878-8","volume":"71","author":"Z Salehi","year":"2021","unstructured":"Salehi Z, et al. RNA sequencing of CD4(+) T cells in relapsing-remitting multiple sclerosis patients at Relapse: deciphering the involvement of novel genes and pathways. J Mol Neurosci. 2021;71(12):2628\u201345.","journal-title":"J Mol Neurosci"},{"issue":"2","key":"3926_CR96","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/cei\/uxae032","volume":"217","author":"L Martin-Gutierrez","year":"2024","unstructured":"Martin-Gutierrez L, et al. Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis. Clin Exp Immunol. 2024;217(2):204\u201318.","journal-title":"Clin Exp Immunol"},{"key":"3926_CR97","doi-asserted-by":"publisher","first-page":"e8357","DOI":"10.7717\/peerj.8357","volume":"8","author":"Z Shang","year":"2020","unstructured":"Shang Z, et al. Identification of key genes associated with multiple sclerosis based on gene expression data from peripheral blood mononuclear cells. PeerJ. 2020;8:e8357.","journal-title":"PeerJ"},{"issue":"1","key":"3926_CR98","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41598-024-51779-0","volume":"14","author":"WZ Yeh","year":"2024","unstructured":"Yeh WZ, et al. Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis. Sci Rep. 2024;14(1):1436.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"3926_CR99","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2119\/molmed.2010.00071","volume":"17","author":"JW Lindsey","year":"2011","unstructured":"Lindsey JW, Agarwal SK, Tan FK. Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T cells. Mol Med. 2011;17(1\u20132):95\u2013102.","journal-title":"Mol Med"},{"issue":"5","key":"3926_CR100","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/brain\/awaa084","volume":"143","author":"S Malhotra","year":"2020","unstructured":"Malhotra S, et al. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain. 2020;143(5):1414\u201330.","journal-title":"Brain"},{"key":"3926_CR101","doi-asserted-by":"publisher","first-page":"700031","DOI":"10.3389\/fimmu.2021.700031","volume":"12","author":"Y Shi","year":"2021","unstructured":"Shi Y, et al. Discovery of Novel biomarkers for Diagnosing and Predicting the Progression of multiple sclerosis using TMT-Based quantitative proteomics. Front Immunol. 2021;12:700031.","journal-title":"Front Immunol"},{"issue":"3","key":"3926_CR102","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1021\/pr3012107","volume":"12","author":"MP Stoop","year":"2013","unstructured":"Stoop MP, et al. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res. 2013;12(3):1101\u20137.","journal-title":"J Proteome Res"},{"key":"3926_CR103","doi-asserted-by":"publisher","first-page":"577091","DOI":"10.1016\/j.jneuroim.2019.577091","volume":"339","author":"AE Nystad","year":"2020","unstructured":"Nystad AE, et al. Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. J Neuroimmunol. 2020;339:577091.","journal-title":"J Neuroimmunol"},{"key":"3926_CR104","doi-asserted-by":"crossref","unstructured":"Bruijstens AL et al. Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood. Mult Scler, 2022: p. 13524585221125369.","DOI":"10.1177\/13524585221125369"},{"issue":"1","key":"3926_CR105","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","volume":"73","author":"RA Farrell","year":"2009","unstructured":"Farrell RA, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009;73(1):32\u20138.","journal-title":"Neurology"},{"issue":"9485","key":"3926_CR106","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","volume":"366","author":"M Keegan","year":"2005","unstructured":"Keegan M, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366(9485):579\u201382.","journal-title":"Lancet"},{"issue":"13","key":"3926_CR107","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1212\/01.wnl.0000326576.91097.87","volume":"71","author":"JD Lunemann","year":"2008","unstructured":"Lunemann JD, et al. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology. 2008;71(13):1033\u20135.","journal-title":"Neurology"},{"issue":"7","key":"3926_CR108","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.autrev.2005.03.005","volume":"4","author":"T Ziemssen","year":"2005","unstructured":"Ziemssen T, Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev. 2005;4(7):460\u20137.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"3926_CR109","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cell.2018.12.012","volume":"176","author":"MA Wheeler","year":"2019","unstructured":"Wheeler MA, et al. Environmental Control of Astrocyte Pathogenic Activities in CNS inflammation. Cell. 2019;176(3):581\u2013e59618.","journal-title":"Cell"},{"issue":"10","key":"3926_CR110","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1523\/JNEUROSCI.0580-20.2021","volume":"41","author":"D Saraswat","year":"2021","unstructured":"Saraswat D, et al. Heparanome-mediated rescue of oligodendrocyte progenitor quiescence following inflammatory demyelination. J Neurosci. 2021;41(10):2245\u201363.","journal-title":"J Neurosci"},{"key":"3926_CR111","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-030-34521-1_4","volume":"1221","author":"F Teixeira","year":"2020","unstructured":"Teixeira F, Gotte M. Involvement of Syndecan-1 and Heparanase in Cancer and inflammation. Adv Exp Med Biol. 2020;1221:97\u2013135.","journal-title":"Adv Exp Med Biol"},{"key":"3926_CR112","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jneuroim.2017.07.001","volume":"310","author":"B Changyaleket","year":"2017","unstructured":"Changyaleket B, et al. Heparanase: potential roles in multiple sclerosis. J Neuroimmunol. 2017;310:72\u201381.","journal-title":"J Neuroimmunol"},{"issue":"10","key":"3926_CR113","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.molimm.2010.03.014","volume":"47","author":"M Bitan","year":"2010","unstructured":"Bitan M, et al. Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis. Mol Immunol. 2010;47(10):1890\u20138.","journal-title":"Mol Immunol"},{"issue":"5","key":"3926_CR114","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1189\/jlb.0507315","volume":"82","author":"AM de Mestre","year":"2007","unstructured":"de Mestre AM, et al. Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4(+) T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene. J Leukoc Biol. 2007;82(5):1289\u2013300.","journal-title":"J Leukoc Biol"},{"issue":"11","key":"3926_CR115","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.exphem.2016.08.006","volume":"44","author":"B Heyman","year":"2016","unstructured":"Heyman B, Yang Y. Mechanisms of heparanase inhibitors in cancer therapy. Exp Hematol. 2016;44(11):1002\u201312.","journal-title":"Exp Hematol"},{"issue":"1","key":"3926_CR116","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/febs.13932","volume":"284","author":"RD Sanderson","year":"2017","unstructured":"Sanderson RD, et al. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J. 2017;284(1):42\u201355.","journal-title":"FEBS J"},{"key":"3926_CR117","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.matbio.2020.06.001","volume":"93","author":"GL Zhang","year":"2020","unstructured":"Zhang GL, et al. Significance of host heparanase in promoting tumor growth and metastasis. Matrix Biol. 2020;93:25\u201342.","journal-title":"Matrix Biol"},{"key":"3926_CR118","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/978-3-030-34521-1_16","volume":"1221","author":"N Higashi","year":"2020","unstructured":"Higashi N, Irimura T, Nakajima M. Heparanase is involved in Leukocyte Migration. Adv Exp Med Biol. 2020;1221:435\u201344.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"3926_CR119","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139.","journal-title":"Nat Med"},{"issue":"5","key":"3926_CR120","first-page":"823","volume":"102","author":"JP Li","year":"2009","unstructured":"Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009;102(5):823\u20138.","journal-title":"Thromb Haemost"},{"issue":"10","key":"3926_CR121","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1111\/febs.12184","volume":"280","author":"A Meirovitz","year":"2013","unstructured":"Meirovitz A, et al. Heparanase in inflammation and inflammation-associated cancer. FEBS J. 2013;280(10):2307\u201319.","journal-title":"FEBS J"},{"issue":"5","key":"3926_CR122","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.matbio.2013.02.008","volume":"32","author":"R Goldberg","year":"2013","unstructured":"Goldberg R, et al. Versatile role of heparanase in inflammation. Matrix Biol. 2013;32(5):234\u201340.","journal-title":"Matrix Biol"},{"issue":"5","key":"3926_CR123","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.matbio.2013.03.001","volume":"32","author":"I Vlodavsky","year":"2013","unstructured":"Vlodavsky I, Iozzo RV, Sanderson RD. Heparanase: multiple functions in inflammation, diabetes and atherosclerosis. Matrix Biol. 2013;32(5):220\u20132.","journal-title":"Matrix Biol"},{"issue":"4","key":"3926_CR124","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.bbagen.2007.12.014","volume":"1780","author":"H Takahashi","year":"2008","unstructured":"Takahashi H, et al. Involvement of heparanase in migration of microglial cells. Biochim Biophys Acta. 2008;1780(4):709\u201315.","journal-title":"Biochim Biophys Acta"},{"key":"3926_CR125","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1742-2094-10-75","volume":"10","author":"S Lively","year":"2013","unstructured":"Lively S, Schlichter LC. The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J Neuroinflammation. 2013;10:75.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"3926_CR126","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neulet.2007.02.075","volume":"417","author":"H Takahashi","year":"2007","unstructured":"Takahashi H, et al. Expression of heparanase in nestin-positive reactive astrocytes in ischemic lesions of rat brain after transient middle cerebral artery occlusion. Neurosci Lett. 2007;417(3):250\u20134.","journal-title":"Neurosci Lett"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03926-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03926-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03926-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:05:25Z","timestamp":1730365525000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03926-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3926"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03926-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of Lishui Second People\u2019s Hospital (Approval number 20171116-3). All research was performed in accordance with the Declaration of Helsinki. All participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}